May 19, 2022 7:00am EDT Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
May 13, 2022 8:00am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
May 11, 2022 8:00am EDT Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference